ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Antimicrobial Resistance-Stratified Efficacy of Vonoprazan, Clarithromycin, and Metronidazole Therapy for
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Choosing an effective Methods: This exploratory, single-arm, open-label interventional study was conducted at Yokohama City University Hospital (jRCTs031200171). Patients with Results: Thirty patients completed the intervention. The overall eradication rate was 90.0% (27/30; 95% confidence interval [CI], 73.5%-97.9%) in per-protocol and intention-to-treat analyses. Adherence was high (99.7%). According to resistance profiles, eradication rates were 100% (15/15; 95% CI, 78.2%-100%) in CAM-susceptible strains, 78.6% (11/14; 95% CI, 49.2%-95.3%) in CAM-resistant strains, 92.0% (23/25; 95% CI, 74.0%-99.0%) in MNZ-susceptible strains, 75.0% (3/4; 95% CI, 19.4%-99.4%) in MNZ-resistant strains, and 50.0% (1/2) in dual-resistant strains. No serious adverse events were documented. Conclusions: A 1-week triple therapy with vonoprazan, CAM, and MNZ is an effective and safe treatment option for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.